Literature DB >> 15652605

Homocysteine and stroke: evidence on a causal link from mendelian randomisation.

Juan P Casas1, Leonelo E Bautista, Liam Smeeth, Pankaj Sharma, Aroon D Hingorani.   

Abstract

BACKGROUND: Individuals homozygous for the T allele of the MTHFR C677T polymorphism have higher plasma homocysteine concentrations (the phenotype) than those with the CC genotype, which, if pathogenetic, should put them at increased risk of stroke. Since this polymorphism is distributed randomly during gamete formation, its association with stroke should not be biased or confounded. We investigated consistency between the expected odds ratio for stroke among TT homozygotes, extrapolated from genotype-phenotype and phenotype-disease studies, and the observed odds ratio from a meta-analysis of genotype-disease association studies.
METHODS: We searched MEDLINE and EMBASE up to June, 2003, for all relevant studies on the association between homocysteine concentration and the MTHFR polymorphism, and until December, 2003, for those on the association between the polymorphism and the risk of stroke. Pooled odds ratios and 95% CI were calculated by random-effects and fixed-effects models. Consistency between expected and observed odds ratios was assessed by interaction test.
FINDINGS: 111 studies met the selection criteria. Among 15635 people without cardiovascular disease, the weighted mean difference in homocysteine concentration between TT and CC homozygotes was 1.93 micromol/L (95% CI 1.38 to 2.47). The expected odds ratio for stroke corresponding to this difference based on previous observational studies was 1.20 (1.10 to 1.31). In our genetic meta-analysis (n=13928) the odds ratio for stroke was 1.26 (1.14 to 1.40) for TT versus CC homozygotes, similar to the expected odds ratio (p=0.29). Consistency between the odds ratios was preserved in analyses by age-group, ethnic background, and geographical location.
INTERPRETATION: The observed increase in risk of stroke among individuals homozygous for the MTHFR T allele is close to that predicted from the differences in homocysteine concentration conferred by this variant. This concordance is consistent with a causal relation between homocysteine concentration and stroke.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15652605     DOI: 10.1016/S0140-6736(05)17742-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  120 in total

1.  Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotype-disease analysis and genotype-disease analysis.

Authors:  A Pezzini; M Grassi; E Del Zotto; D Assanelli; S Archetti; R Negrini; L Caimi; A Padovani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04-19       Impact factor: 10.154

Review 2.  Genetics of stroke.

Authors:  Jin-min Guo; Ai-jun Liu; Ding-feng Su
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 3.  Methodological challenges in mendelian randomization.

Authors:  Tyler J VanderWeele; Eric J Tchetgen Tchetgen; Marilyn Cornelis; Peter Kraft
Journal:  Epidemiology       Date:  2014-05       Impact factor: 4.822

4.  MTHFR 677 TT genotype and hyperhomocysteinaemia: an underestimated risk TANDEM for patients with stroke.

Authors:  V Caso; M Paciaroni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-16       Impact factor: 10.154

Review 5.  Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence.

Authors:  David S Wald; Nicholas J Wald; Joan K Morris; Malcolm Law
Journal:  BMJ       Date:  2006-11-25

6.  A direct assessment of genetic contribution to the incidence of coronary infarct in the general population Greek EPIC cohort.

Authors:  Nikos Yiannakouris; Antonia Trichopoulou; Vassiliki Benetou; Theodora Psaltopoulou; Jose M Ordovas; Dimitrios Trichopoulos
Journal:  Eur J Epidemiol       Date:  2006-11-22       Impact factor: 8.082

7.  Homocysteine and leukoaraiosis: time for a clinical trial?

Authors:  S Sacco; A Carolei
Journal:  Neurol Sci       Date:  2007-10       Impact factor: 3.307

8.  Plasma homocysteine and risk of mild cognitive impairment.

Authors:  Christiane Reitz; Ming-Xin Tang; Joshua Miller; Ralph Green; José A Luchsinger
Journal:  Dement Geriatr Cogn Disord       Date:  2008-12-16       Impact factor: 2.959

9.  Homocysteine and cardiovascular disease: should we treat?

Authors:  Kathleen Potter
Journal:  Clin Biochem Rev       Date:  2008-02

10.  Two siblings with a homozygous MTHFR C677T (G80A-RFC1) mutation and stroke.

Authors:  Massimo Barbagallo; Piero Pavone; Gemma Incorpora; Andrea Domenico Praticò; Olga Romantshik; Simonetta Friso; Alberto Spalice; Francesco Nicita; Agata Polizzi; Martino Ruggieri; Paola Iannetti
Journal:  Childs Nerv Syst       Date:  2008-10-29       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.